PURASORB PDLG 7502 is an acid-terminated poly(DL-lactide-co-glycolide) with a nominal monomer ratio of 75:25 and an inherent viscosity midpoint of 0.2 dL/g measured in chloroform at 25°C and 0.1 g/dL. The acid terminus accelerates bulk hydrolysis relative to ester-capped grades of the same lactide-to-glycolide ratio, and the low inherent viscosity limits organic-phase viscosity during solvent-based encapsulation. These properties set processing boundaries for parenteral sustained-release dosage forms: solvent removal must be controlled to avoid early porosity, melt processing must be bounded to avoid monomer regeneration, and all terminal product forms require aseptic fill or validated terminal sterilization. The downstream applications below are restricted to established drug-device and pharmaceutical categories in which 75:25 PLGA has published industrial use; sectors without parenteral or implantable regulatory pathways are excluded.

Why Does Acid-Terminated 75:25 PLGA Dominate Microsphere Encapsulation?

The use of PDLG 7502 in microsphere encapsulation is driven by its acid-terminated chain ends and low inherent viscosity midpoint of 0.2 dL/g. In a water-in-oil-in-water double emulsion, the dispersed phase is prepared by dissolving the copolymer at 10–20% w/v in dichloromethane together with the active pharmaceutical ingredient at a drug-to-polymer ratio between 1:5 and 1:10, while the continuous aqueous phase contains 0.25–1.0% w/v poly(vinyl alcohol) with a hydrolysis degree of 88% and a molecular weight below 30 kDa to maintain interfacial tension low enough for primary emulsion stability. The acid terminus promotes hydration and matrix degradation after injection, but it also increases carboxylic acid density at the oil-water interface during solvent extraction; this creates a measurable drop in encapsulation efficiency when the pH of the outer phase falls below 5.5, requiring buffering with 20–50 mM phosphate at pH 7.0–7.4 in production-scale batches. The compliance envelope is defined by ICH Q3C(R8) for residual dichloromethane in the finished lyophilisate at a Class 2 solvent limit of 600 ppm, USP <85> for bacterial endotoxins with a typical release specification of <0.5 EU/mg for parenteral microspheres, and USP <790> for visible particulate inspection after reconstitution.

Production-scale microsphere manufacturing for PDLG 7502 typically proceeds through a rotor-stator primary emulsification step in a Silverson L5M-A-type mixer operated at tip speeds of 5–10 m/s for 30–120 s. The coarse water-in-oil emulsion is transferred into a jacketed glass or stainless steel reactor with an overhead paddle impeller running at 200–400 rpm, where the solvent is extracted at 35–40°C for 4–6 h. Because the low intrinsic viscosity of PDLG 7502 lowers the elastic component of the dispersed phase, droplet breakage is rapid but droplet coalescence also increases if the external phase PVA concentration drops below 0.25% w/v; this is the primary batch-failure mode observed on pilot lines, manifesting as a bimodal particle size distribution with an upper mode above 200 µm and low drug loading. The finished microspheres are collected on 20 µm stainless steel sieves, washed with water for injection, and lyophilized with 5% w/w mannitol as an external cryoprotectant; residual moisture below 2.0% is required to retard premature hydrolysis during shelf storage.

Terminal finished products include single-dose vials of lyophilized microspheres for reconstitution with 1.0–2.5 mL of sterile diluent immediately before intramuscular or subcutaneous injection, and combination kits containing a preloaded diluent syringe and vented vial adapter. The low acid-terminated molecular weight makes this grade suitable for release durations of approximately 4–8 weeks in aqueous physiological media, but published data for a specific active pharmaceutical ingredient must be confirmed by in vitro release testing under sink conditions in phosphate-buffered saline at 37°C and pH 7.4.

A 20–45 wt% solution of PDLG 7502 in anhydrous N-methyl-2-pyrrolidone forms a polymer-rich injectable vehicle that precipitates at the subcutaneous or intratumoral injection site as the solvent exchanges with physiological water. In-situ depot manufacturing with PDLG 7502 uses a polymer addition ratio of 20–45 wt% in NMP and a drug loading of 2–15 wt% depending on API solubility in the polymer-solvent matrix; the copolymer is added under dry nitrogen, mixed in a planetary mixer at 25°C until the solution reaches a clear point, and then held under vacuum to degas entrapped air. The compatibility envelope includes ICH Q3C(R8) for NMP with a permitted daily exposure of 5.3 mg/day and a concentration limit of 530 ppm, USP <788> for subvisible particulates in the finished prefilled syringe, and USP <71> sterility because terminal sterilization by steam or gamma is not viable for NMP-containing PLGA solutions. The process cannot rely on terminal filtration if the dissolved polymer solution exceeds approximately 150 cP at 25°C; instead, the vehicle and API are sterilized separately through 0.22 µm PVDF filters before compounding in an ISO 5 aseptic environment, a constraint that limits the use of thermolabile APIs and requires continuous bioburden monitoring under 21 CFR 211.113.

The injection device is typically a single-use prefillable syringe with a 21G or 23G needle; the formulation is filled under a nitrogen blanket to prevent oxidative degradation of NMP. Upon injection, the NMP diffuses into the interstitial fluid at a rate controlled by the polymer-rich surface skin, and the PDLG 7502 precipitates into a solid depot with an initial burst that is higher than that of microsphere products partly because the solvent-rich surface region is not fully extracted before body fluid influx. Operational boundaries include a residual water content below 0.5% in the compounding stage, because water competes with NMP for hydrogen bonding and causes local polymer aggregation before fill. Terminal product types in this category are prefilled syringes containing 0.5–2.0 g of the in-situ-forming matrix, occasionally co-packaged with a desiccant pouch and a needle safety device.

Thermal History Control in Low-IV PLGA Extrusion

Subdermal implant rods based on PDLG 7502 are manufactured by hot-melt extrusion or injection molding with an API loading between 20 wt% and 50 wt% in the polymer matrix; the low inherent viscosity allows barrel-zone temperatures to be set at 90–110°C, which is 20–40°C below the temperatures required for higher molecular weight PLGA grades. This lower melt temperature is an advantage for heat-sensitive APIs, but the acid-terminated copolymer is prone to autocatalytic chain scission if the melt residence time exceeds 5 min or if the feed moisture is above 0.05% w/w. The production sequence uses a co-rotating twin-screw extruder with an L/D ratio of at least 25:1, gravimetric feeding of a pre-blended polymer-API mixture, and a 1.0–2.0 mm rod die; the extrudate is cooled on a 4°C stainless steel belt and cut to a controlled length. The compliance package is governed by EN ISO 10993-1:2018 biological evaluation planning, EN ISO 10993-5:2009 for cytotoxicity, EN ISO 10993-6:2016 for local effects after implantation, and USP <88> Class VI for polymeric components, with final sterility achieved by gamma irradiation at 25–40 kGy only after confirming that the API degradation products remain within ICH limits.

On manufacturing lines, the primary failure mode is the appearance of lactide and glycolide monomer in the extrudate, detected by gas chromatography as an increase in total residual monomers above 0.5% w/w; this condition correlates with a visible yellowing of the rod and a decrease in molecular weight. The acid terminus of PDLG 7502 accelerates moisture- and heat-induced hydrolysis, so pre-drying is conducted under vacuum at 40°C for at least 12 h whenever the copolymer has been exposed to ambient air above 60% RH for more than 30 min. A nitrogen purge is maintained on the hopper and feed throat, and the die pressure is monitored at <150 bar because excessive backpressure indicates high melt viscosity and induces shear heating. Terminal products include single-rod subcutaneous kits preloaded in trocar applicators and multi-rod configurations for higher-dose indications, with release rates governed by drug loading and rod surface-area-to-volume ratio.

Nanoprecipitation of PDLG 7502 for intravenous oncology applications uses a dispersed-phase concentration of 1–5% w/v in a water-miscible solvent such as acetone or ethyl acetate, with a drug-to-polymer ratio from 1:5 to 1:20 and a stabilizer concentration of 0.1–0.5% w/v poloxamer 188 in the aqueous phase. The organic phase is injected into 10–20 volumes of aqueous phase under controlled mixing at 200–500 rpm using a syringe pump or tangential-flow solvent diffusion cell; the resulting nanoparticle dispersion is concentrated by ultrafiltration through a 100 kDa membrane and lyophilized with 5–10% w/w trehalose. The finished product must meet ISO 22412:2017 by dynamic light scattering, with a Z-average target of 120–200 nm and a polydispersity index below 0.15, because particles above 200 nm shift the distribution toward rapid hepatic clearance and particles below 100 nm can exhibit higher burst release due to increased specific surface area. The compliance envelope includes ISO 10993-4:2017 for hemocompatibility, USP <787> for subvisible particles in therapeutic protein injectables, and ICH Q3C(R8) for residual acetone or ethyl acetate. Processing limitations include the inability to terminal-filter the organic solvent prior to particle formation; instead, the solvent is removed by rotary evaporation under vacuum at 35°C and the aqueous dispersion is sterile-filtered through a 0.22 µm membrane if the article size distribution remains entirely below the membrane exclusion threshold. Terminal product configurations are single-use vials of lyophilized nanoparticles for reconstitution in 5% dextrose or saline injection.

PLGA 75:25 Antigen-Loaded Microparticle Process Windows

Antigen-loaded microparticles using PDLG 7502 are prepared by a primary water-in-oil emulsion in which the inner aqueous phase contains 2–5% w/v trehalose and the antigen at an antigen-to-polymer mass ratio of 1:50 to 1:200, with the oil phase composed of 8–15% w/v PLGA in dichloromethane. The primary emulsion is formed in a high-shear mixer at 10,000–20,000 rpm for 30–60 s and then transferred into a 0.1–1.0% w/v poly(vinyl alcohol) solution for secondary emulsification. For spray-dried vaccine microparticles, the feed dispersion is atomized through a two-fluid nozzle at an inlet temperature of 55–65°C and an outlet temperature of 35–40°C; these temperatures are deliberately below the denaturation onset of most protein antigens but above the glass-transition temperature of PDLG 7502, creating a partial surface coalescence that reduces initial release. Compliance is governed by 21 CFR 610.12 sterility, Ph. Eur. 2.6.14 bacterial endotoxins, 21 CFR 211.113 for microbiological control, and Ph. Eur. 5.1.1 for sterile preparation methods. Terminal products include dry-powder vaccine microparticles for reconstitution, single-dose combination vaccine vials, and dry presentations for solid-dose injection. Published data for this specific low-IV acid-terminated grade in antigen microparticle configurations is limited to academic-scale studies; industrial qualification requires antigen-specific stability screening and immunization challenge studies.

When Sterile Filtration Is Not Feasible in Low-Viscosity PLGA Solutions

Intravitreal depot formulations with PDLG 7502 are based on a polymer concentration of 10–18% w/v in ethyl acetate or benzyl alcohol, with a corticosteroid or anti-VEGF small-molecule payload at a drug-to-polymer ratio of 1:5 to 1:10. The microsphere or suspension product for ophthalmic use carries the strictest particulate and endotoxin requirements in the PDLG 7502 application set: USP <789> for particulate matter in ophthalmic solutions, USP <85> for bacterial endotoxins with a typical release specification below 0.2 EU/mg, and EN ISO 10993-1:2018 for ophthalmic tissue interaction. Because the PLGA solution is not reliably sterile-filterable after particle formation, the manufacturing line uses aseptic solvent evaporation and lyophilization, with all excipients sterilized separately and a final dry powder filled into single-dose containers in an ISO 5 isolator.

The target particle size for intravitreal injection is 25–75 µm; particles below 10 µm are removed by cascade sieving because they can migrate through the trabecular meshwork and increase intraocular pressure, while particles above 100 µm can occlude a 27G needle. The vehicle is often a 0.3–0.5% w/v sodium hyaluronate solution in balanced salt solution to provide shear-thinning behavior and improve suspension uniformity during injection. The terminal product is a preloaded intravitreal injection kit containing a 0.5–1.0 mL suspension, a 27G thin-wall needle, and a sterile filter needle for withdrawal. In this application, the main processing conflict is that the same acid terminus that accelerates intraocular degradation also raises the rate of hydrolysis during sterilization and storage; therefore, vacuum drying to residual moisture below 1.5% and cold-chain storage at 2–8°C are mandatory.